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ABSTRACT
Background. The impact of arteriovenous fistula (AVF) or graft (AVG) thrombosis on mortality has been sparsely studied. This
study investigated the association between AVF/AVG thrombosis and all-cause and cardiovascular mortality.
Methods. The data from 2439 patients with AVF or AVG undergoing maintenance haemodialysis (HD) included in the A
Study to Evaluate the Use of Rosuvastatin in Subjects on Regular Hemodialysis: An Assessment of Survival and
Cardiovascular Events trial (AURORA) were analysed using a time-dependent Cox model. The incidence of vascular access
(VA) thrombosis was a pre-specified secondary outcome.
Results. During follow-up, 278 AVF and 94 AVG thromboses were documented. VA was restored at 226 64 days after
thrombosis (27 patients had no restoration with subsequent permanent central catheter). In multivariable survival analysis
adjusted for potential confounders, the occurrence of AVF/AVG thrombosis was associated with increased early and late all-
cause mortality, with a more pronounced association with early all-cause mortality {hazard ratio [HR]<90 days 2.70 [95%
confidence interval (CI) 1.83–3.97], P<0.001; HR>90 days 1.47 [1.20–1.80], P<0.001}. In addition, the occurrence of AVF
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thrombosis was significantly associated with higher all-cause mortality, whether VA was restored within 7 days [HR 1.34
(95% CI 1.02–1.75), P¼0.036] or later than 7 days [HR 1.81 (95% CI 1.29–2.53), P¼0.001].
Conclusions. AVF/AVG thrombosis should be considered as a major clinical event since it is strongly associated with
increased mortality in patients on maintenance HD, especially in the first 90 days after the event and when access
restoration occurs>7 days after thrombosis. Clinicians should pay particular attention to the timing of VA restoration and
the management of these patients during this high-risk period. The potential benefit of targeting overall patient risk with
more aggressive treatment after AVF/AVG restoration should be further explored.
Keywords: arteriovenous fistula, arteriovenous graft, cardiovascular mortality, chronic haemodialysis, survival, vascular
access complication
INTRODUCTION
Vascular access (VA) is the ‘lifeline’ of patients on chronic
haemodialysis (HD). However, it is also the source of specific
complications, such as bleeding and infections (either local or
systemic), and requires urgent intervention, particularly in cases
of thrombosis [1]. Native arteriovenous fistula (AVF) is currently
the best VA when technically feasible, according to the interna-
tional dialysis guidelines [2–4]. Their use is associated with better
patient survival compared with arteriovenous graft (AVG) or cath-
eters [2]. Mechanisms leading to stenosis or thrombosis of AVF/
AVG are poorly elucidated. In particular, the contribution of sys-
temic factors (age, hypercoagulability, chronic inflammation,
poor vascular state etc.) in addition to local factors (i.e. initial sur-
gical procedure, quality of the anastomosis, mechanical lesions
linked to repeated cannulations etc.) is uncertain [5, 6].
Cardiovascular (CV) disease is a major cause of mortality in
dialysis. Although CV mortality has decreased among dialysis
patients in the past decades [7], the rate of CV outcome of these
patients is still dramatically higher than the general population.
Classical therapeutic interventions such as statins have failed
to improve CV mortality in dialysis and classical scores are sub-
optimal in predicting mortality in dialysis.
To date, no study has investigated the impact of AVF/AVG
failure on mortality among patients on HD. While VA failure
may increase mortality by way of poor dialysis adequacy or
complications related to revascularization, it is our hypothesis
that such failure, especially with AVF, is a marker of poor gen-
eral state: AVF/AVG thrombosis could consequently serve as an
integrative short- and midterm risk stratifier in HD patients.
Whether AVF/AVG failure represents an important risk stratifier
may have substantial clinical implications since it could pro-
mote a closer follow-up after restoration of VA access, with pos-
sibly a more aggressive treatment not limited to VA access
restoration also targeting overall patient risk.
In light of the above, this study aimed to assess the associa-
tion between VA complications with all-cause and CV mortality
in dialysis patients from the large multicentre, randomized con-
trol A Study to Evaluate the Use of Rosuvastatin in Subjects on
Regular Hemodialysis: An Assessment of Survival and
Cardiovascular Events (AURORA), which recorded VA failure as
a pre-specified secondary outcome [8, 9].
MATERIALS ANDMETHODS
Study population
Analyses were performed on the AURORA data for which results
have previously been reported [8–10]. The study obtained institu-
tional review board approval. Briefly, the AURORA was a random-
ized, double-blind, placebo-controlled, multicentre study
involving 2776 patients, 50–80 years of age, who were undergoing
maintenance HD for at least 3 months (ClinicalTrials.gov number
NCT00240331). After providing written informed consent,
patients were randomly assigned to receive rosuvastatin, 10 mg
daily or placebo. Exclusion criteria are detailed in the supplemen-
tary data. For this analysis, patients with a tunnelled central ve-
nous dialysis catheter (n¼ 316) or with missing data regarding VA
(n¼ 21) were excluded. During a median follow-up period of
3.8 years, the initiation of treatment with rosuvastatin had no sig-
nificant effect on the composite primary endpoint of death from
CV causes, non-fatal myocardial infarction or non-fatal stroke
{hazard ratio [HR] 0.96 [95% confidence interval (CI) 0.84–1.11]}.
Rosuvastatin also exhibited no significant effects on the inci-
dence of procedures as a result of stenosis or thrombosis of the
VA for long-term dialysis (AVF and AVG only) compared with pla-
cebo [HR 1.10 (95% CI 0.95–1.27)], the latter constituting one of the
pre-specified secondary endpoints of the trial. All events recorded
during the trial were reviewed and adjudicated by a clinical end-
point committee to ensure consistency of the event diagnosis.
Definition of stenosis and thrombosis
As pre-specified by the protocol [8], a corrective procedure for VA
thrombosis was considered as the intervention required upon oc-
currence of VA failure. This excluded saline or heparin flushing
while including the following: thrombolysis, angioplasty with or
without stent, surgical refashioning and new access site creation.
Statistical analysis
Statistical methods are detailed in the supplementary data.
Briefly, statistical analyses were performed using Statistical
Package for the Social Sciences, SPSS version 22 software (IBM,
Armonk, NY, USA). Descriptive statistics are reported as percen-
tages for categorical variables and mean 6 SD for continuous
variables. Comparisons of baseline characteristics were carried
out using t-test, analysis of variance or chi-squared tests as re-
quired. VA thrombosis-free survival was calculated using the
Kaplan–Meier formula and survival curves plotted accordingly.
Associations between baseline characteristics and the occur-
rence of thrombosis during follow-up and between the occur-
rence of thrombosis during follow-up and all-cause mortality or
CV mortality were assessed using the Cox proportional hazards
model. VA thrombosis was used as a time-dependent variable.
Moreover, since a significant interaction with time was identi-
fied, separate Cox models were fitted for the following time
intervals: <90 and >90 days after the VA thrombosis. Finally, to
better assess the impact of the timing of VA restoration on out-
come, the association of VA thrombosis with VA restoration
within 7 days and later than 7 days was evaluated by creating
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two time-dependent variables. Survival analyses were also car-
ried out separately according to the VA type.
Finally, analyses were also conducted for the composite pri-
mary endpoint of the AURORA (composite endpoint of death from
CV causes, non-fatal myocardial infarction or non-fatal stroke).
RESULTS
Baseline characteristics of patients according to the type
of vascular access (arteriovenous fistula or
arteriovenous graft) and the presence of a thrombosis of
the vascular access during follow-up
Patients with AVF (n¼ 2199) differed from patients with AVG
(n¼ 240) for several baseline factors. Other than AVF patients
being more frequently male (65.6 versus 46.2%; P< 0.001),
AVG patients had more CV risk factors, including more
frequent ischaemic heart disease (17.5 versus 11.9%; P¼ 0.02),
longer dialysis duration (5.956 6.42 years versus 4.5265.21;
P¼ 0.001) and higher high-sensitivity C-reactive protein (hs-
CRP) (1.1361.26 mg/L versus 0.9661.13; P¼ 0.05).
In AVF patients, those experiencing thrombosis requiring a
procedure had a more frequent history of peripheral arterial dis-
ease than those without VA complication (Table 1; P¼ 0.03).
Both systolic (SBP) and diastolic blood pressure (DBP) were lower
in patients with thrombosis. The baseline serum albumin level
was lower in patients with AVF experiencing thrombosis during
follow-up. Likewise, in AVG patients, SBP and DBP were mark-
edly lower in patients with thrombosis (P< 0.001). The propor-
tion of current smokers was surprisingly lower in the group of
AVG patients with thrombosis (P¼ 0.006).
Baseline predictors of the thrombosis of the vascular
access (arteriovenous fistula or arteriovenous graft)
during follow-up
A total of 94 AVG thromboses and 278 AVF thromboses were
documented during follow-up. Patients with AVG had a higher
risk of thrombosis (Figure 1; P< 0.001). In multivariable analysis,
baseline characteristics associated with an increased rate of VA
thrombosis during follow-up were VA type [AVG versus AVF:
HR 4.79 (95% CI 3.70–6.19); P< 0.001], older age, lower SBP,
Table 1. Baseline characteristics and recorded outcomes of patients with VA thrombosis during follow-up in comparison with patients with no
VA complications according to VA type











Age (years) 63.78 6 8.71 64.69 6 8.46 0.10 63.38 6 8.33 64.61 6 8.14 0.26
Years on RRT 4.52 6 5.20 4.49 6 5.33 0.93 6.12 6 6.47 5.68 6 6.35 0.60
Measured Kt/V 1.44 6 0.56 1.43 6 0.59 0.82 1.49 6 0.41 1.42 6 0.33 0.17
Albumin (g/L) 39.98 6 3.40 39.48 6 3.44 0.02 39.57 6 3.08 39.33 6 2.77 0.54
Haemoglobin (g/dL) 11.69 6 1.61 11.70 6 1.49 0.87 11.79 6 1.57 11.84 61.50 0.81
hs-CRP (mg/L) 0.95 6 1.12 1.04 6 1.21 0.24 1.10 6 1.21 1.18 6 1.35 0.62
BMI (kg/m2) 25.27 6 4.64 24.93 6 4.47 0.24 25.48 6 5.43 26.22 6 5.91 0.32
SBP (mmHg) 137.96 6 24.22 132.22 6 22.93 <0.001 140.12 6 26.19 125.24 6 23.61 <0.001
DBP (mmHg) 76.20 6 12.62 74.41 6 12.41 0.03 76.94 6 12.41 70.02 6 12.58 <0.001
Male gender (%) 66.0 62.6 0.28 43.2 51.1 0.24
Current smoker (%) 15.2 14.0 0.65 24.0 9.6 0.006
Diabetes (%) 25.0 24.1 0.77 24.7 27.7 0.65
Peripheral artery disease (%) 13.7 18.7 0.03 18.5 19.1 1.00
History of coronary disease 12.1 10.1 0.37 16.4 19.1 0.60
Platelet inhibitors (%) 41.4 38.1 0.33 61.0 53.2 0.28
Rosuvastatin (%) 49.8 48.2 0.65 50.0 59.6 0.19
Intervention for VA complication, n (%)
Thrombolysis N/A 48 (17.3) N/A N/A 25 (26.6) N/A
Angioplasty 6 stent 33 (11.9) 15 (16.0)
Surgical refashioning 69 (24.8) 29 (30.9)
New access needed 125 (45.0) 25 (26.6)
Unknown 3 (1.1) 0 (0)
Number of deaths, n (%) 835 (43.5) 127 (45.7) N/A 77 (52.7) 46 (48.9) N/A
<90 days after thrombosis, n (%) N/A 28 (10.1) N/A N/A 5 (5.3) N/A
>90 days after thrombosis, n (%) N/A 99 (35.6) N/A N/A 41 (43.6) N/A
Cause of death, n (%)
Coronary heart disease 273 (32.7) 33 (26.0) N/A 17 (22.1) 15 (32.6) N/A
Other cardiac cause 44 (5.3) 7 (5.5) N/A 4 (5.2) 3 (6.5) N/A
Other vascular cause 62 (7.4) 12 (9.4) N/A 6 (7.8) 2 (4.3) N/A
Other CV cause 1 (0.2) 0 (0) N/A 0 (0) 0 (0) N/A
Stroke 49 (5.9) 8 (6.3) N/A 3 (3.9) 3 (6.5) N/A
Non-CV cause 320 (38.3) 60 (47.2) N/A 35 (45.5) 20 (43.5) N/A
Non-adjudicated death 86 (10.3) 7 (5.5%) N/A 12 (15.6) 3 (6.5) N/A
Results with p value less than 5% were emphasized using bold letters.
BMI, body mass index; N/A, not applicable; RRT, renal replacement therapy.
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hypoalbuminaemia and platelet inhibitor medication. In AVF
patients, older age, hypoalbuminaemia and lower SBP were as-
sociated with increased risk of AVF thrombosis. In the AVG
group, only a lower SBP was significantly associated with in-
creased risk of VA thrombosis. Although associated with CV
outcomes (data not shown), hs-CRP was not associated with the
risk of AVF/AVG thrombosis. Predictors of VA thrombosis in
multivariable models for all patients and according to VA type
are presented in Supplementary data, Table S1.
Associations between the complications of the vascular
access (arteriovenous fistula or arteriovenous graft) and
outcomes
Given the significant interaction with time for all-cause mortal-
ity (P¼ 0.005) and CV mortality (P¼ 0.038), the associations be-
tween thrombosis and mortality were expressed according to
two time periods (<90 or >90 days after AVF/AVG thrombosis).
During the follow-up, 1085 deaths were recorded, 962 among
patients with AVF and 123 among patients with AVG (Table 1).
As shown in Figure 2 (and in Supplementary data, Table S2), in
multivariable analysis, AVF/AVG thrombosis was associated
with increased early (<90 days) all-cause mortality [HR 2.70 (95%
CI 1.83–3.97), P< 0.001] and, to a lesser extent, with late
(>90 days) all-cause mortality [HR 1.48 (95% CI 1.20–1.79),
P< 0.001]. Similar results were observed for CV mortality as well
as for the composite endpoint of death from CV causes, non-fa-
tal myocardial infarction or non-fatal stroke.
Associations between the thrombosis of the vascular
access (arteriovenous fistula or arteriovenous graft) and
mortality
AVF thromboses were strongly associated with early and late
all-cause mortality [HR 3.07 (95% CI 2.01–4.71), P< 0.001 and HR
1.50 (95% CI 1.19–1.88), P¼ 0.001, respectively]. No significant as-
sociation was observed between AVG thrombosis and mortality
[HR for early all-cause mortality¼ 1.70 (95% CI 0.67–4.34),
P¼ 0.27 and HR for late all-cause mortality¼ 1.31 (95% CI 0.83–
2.05), P¼ 0.25]. There was no significant interaction between VA
type and VA thrombosis (P for interaction >0.20 for both early
and late all-cause mortality).
Associations between the thrombosis of the vascular
access (arteriovenous fistula or arteriovenous graft) and
mortality according to the timing of the vascular access
restoration
The association of AVF/AVG thrombosis on mortality was eval-
uated in instances of early (<7 days) or delayed (>7 days) AVF/
FIGURE 1: Death-censored survival free of VA complications during follow-up
according to the type of VA (AVF or AVG).
FIGURE 2: Association in multivariable analysis [adjusted for age, gender, years on
RRT, type of VA (when applicable), current smoking, diabetes, history of coronary
disease, history of peripheral arterial disease, BMI, systolic blood pressure, calcu-
lated Kt/V, albumin level, haemoglobin level and hsCRP level (at baseline), platelet
inhibitors and rosuvastatin] between VA complications and (A) all-cause and (B)
CV mortality, as well as on (C) the composite endpoint of death from CV causes,
non-fatal myocardial infarction or non-fatal stroke according to type of VA and
type of complication. Results are presented as HR with 95% CIs. NA, not available.
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AVG restoration. Of note, AVF/AVG thrombosis was signifi-
cantly associated with all-cause mortality when AVF/AVG resto-
ration occurred both within 7 days and later than 7 days,
although the association was more pronounced when AVF/AVG
restoration occurred later [HR 1.26 (95% CI 1.00–1.59) and HR
1.78 (95% CI 1.29–2.38), respectively]. Similar associations were
also observed in AVF patients.
DISCUSSION
To the best of our knowledge, this study is the first to assess the
association between AVF/AVG thrombosis and mortality. In this
large multicentre randomized controlled trial, AVF/AVG throm-
bosis was found to be associated with high mortality, in particu-
lar for early all-cause and CV mortality following thrombosis. Of
note, the association with increased long-term mortality risk,
while mitigated, also persisted even in instances of rapid AVF/
AVG restoration performed within a delay of 7 days. These
results suggest that AVF/AVG thrombosis should be considered
as a major clinical event. In addition, particular attention
should likely be paid to the timing of AVF/AVG restoration as
well as the short- and midterm management of these patients
following AVF/AVG thrombosis.
Evidence of an impact of vascular access failure on
survival
In international guidelines [2, 3], prevention of VA dysfunction
is recommended in order to avoid underdialysis as well as to
prevent thrombosis. Clinical trials have assessed the impact of
active VA surveillance and preventive interventions for VA ste-
nosis on VA survival, but not on patient survival [11].
Nonetheless, two large studies [12, 13] have reported that con-
version from a permanent VA to a catheter is associated with
increased mortality, thus indirectly suggesting an impact of VA
failure on mortality. This study accordingly indicates a strong
association of VA thrombosis on patient survival.
Vascular access thrombosis is associated with increased
mortality: pathophysiological hypotheses
Various mechanisms may explain poor short-term survival fol-
lowing VA thrombosis, including hydroelectrolytic abnormali-
ties related to the incapacity to perform a dialysis session, the
need for a temporary catheter, complications associated with
central catheter placement [14] as well as the revascularization
procedure. The primary complications of endovascular angio-
plasty and thrombectomy include vein rupture, pulmonary em-
bolism and peripheral arterial embolization [15]. However, the
reported complication rates have been low, with the latter being
of minor severity in most instances [15, 16]. Such immediate
complications are likely not responsible for the increase in long-
term CV mortality observed in this study.
Long-term use of a central catheter as a VA is a well-known
factor associated with an increased risk of mortality in dialysis
[17]. Importantly, considering that the increased risk of mortal-
ity is observed even in the case of rapid or immediate VA resto-
ration (<7 days), the association between VA failure and
mortality would suggest that the latter is not solely the conse-
quence of long-term dialysis inadequacy [18] or the deleterious
impact of long-term central catheter use as a VA [17].
VA thrombosis is likely a risk marker, that is, a consequence
of risk factors yet to be identified, associated with poor CV out-
come. Increased coagulation activation has been observed in di-
alysis patients and may be partially involved in VA
complications [6]. VA thrombosis is also putatively related to
systemic pathological conditions, as highlighted by the de-
crease in serum albumin level and weight loss, which could ac-
count for an increased CV mortality [13]. However, hs-CRP,
which was previously shown to be a strong predictor of CV out-
come [19, 20], was not associated with VA thrombosis in this
Table 2. Impact of VA thrombosis and time to VA restoration (< or >7days) on all-cause mortality according to VA type
All patients (events, n¼ 959) AVFs (events, n¼846) AVGs (events, n¼ 113)
Variables HR (95% CI) P-value HR (95% CI) P-value HR (95% CI) P-value
Age (years) 1.04 (1.03–1.05) <0.0001 1.04 (1.03–1.05) <0.0001 1.05 (1.02–1.08) <0.0001
Time on RRT (for 1 year) 1.01 (1.00–1.03) 0.07 1.01 (1.00–1.03) 0.08 1.01 (0.98–1.05) 0.43
Albumin (for 1 g/L) 0.96 (0.94–0.98) <0.001 0.95 (0.93–0.97) <0.001 1.02 (0.94–1.10) 0.66
Haemoglobin (for 1 g/dL) 0.94 (0.90–0.98) 0.003 0.94 (0.90–0.98) 0.004 0.90 (0.78–1.03) 0.13
One log increase in hs-CRP 1.24 (1.17–1.31) <0.001 1.24 (1.17–1.32) <0.001 1.19 (1.02–1.40) 0.027
BMI (for one kg/m2) 0.98 (0.97–0.99) 0.015 0.98 (0.97–1.00) 0.048 0.97 (0.93–1.02) 0.23
SBP (for one mmHg) 1.00 (1.00–1.01) 0.08 1.00 (0.99–1.01) 0.11 1.00 (0.99–1.01) 0.49
Male gender 0.89 (0.77–1.03) 0.11 0.90 (0.78–1.05) 0.19 0.83 (0.54–1.27) 0.40
Current smoking 1.28 (1.07–1.53) 0.007 1.34 (1.11–1.63) 0.003 0.97 (0.57–1.66) 0.91
Diabetes 1.55 (1.34–1.80) <0.001 1.51 (1.29–1.77) <0.001 1.92 (1.25–2.96) 0.003
Peripheral artery disease 1.33 (1.13–1.57) 0.001 1.39 (1.16–1.66) <0.001 1.07 (0.66–1.74) 0.78
History of coronary disease 1.43 (1.20–1.71) <0.001 1.43 (1.18–1.73) <0.001 1.43 (0.89–2.29) 0.14
Kt/V 0.65 (0.50–0.84) 0.001 0.66 (0.50–0.87) 0.003 0.59 (0.26–1.36) 0.22
AVG (AVF is reference group) 1.04 (0.84–1.28) 0.71 – – – –
Platelet inhibitors 1.07 (0.93–1.22) 0.34 1.08 (0.94–1.25) 0.27 0.94 (0.60–1.47) 0.79
Rosuvastatin 0.99 (0.88–1.13) 0.94 0.98 (0.86–1.13) 0.83 1.06 (0.72–1.58) 0.76
Thrombosis with restoration of the VA in <7 days 1.26 (1.00–1.59) 0.049 1.34 (1.02–1.75) 0.036 1.06 (0.66–1.70) 0.82
Thrombosis with restoration of the VA in >7 days 1.78 (1.29–2.38) <0.001 1.81 (1.29–2.53) 0.001 1.37 (0.62–3.06) 0.44
BMI, body mass index; RRT, renal replacement therapy.
Results with p value less than 5% were emphasized using bold letters.
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study. Uremic vasculopathy could also be involved, having been
highlighted in both the pathophysiology of VA maturation fail-
ure and stenosis/thrombosis [21, 22] as well as evoked in in-
creased CV mortality observed in end-stage renal disease
(ESRD) [23, 24]. Specifically, as part of the histological findings of
the large prospective multicentre Hemodialysis Fistula
Maturation Cohort Study, Alpers et al. [25] recently reported that
luminal narrowing was more frequent in patients with CV dis-
ease or peripheral vascular disease. Thus VA thrombosis could
probably represent a marker of the severity of the vascular state
of these patients.
Limitations of the study
This study is a post hoc analysis of a randomized trial and the as-
sociation observed between AVF thrombosis and survival may
potentially be the result of residual confounding. However, all
analyses were adjusted on validated predictors of mortality in
dialysis. Importantly, we did not adjust for variables collected
during follow-up, which could have decreased the association
between VA failure and outcome. However, the objective of our
analysis was risk stratification rather than causal inference. VA
failure seemingly represents a marker of higher risk of death as
a result of other factors occurring during the follow-up.
Nonetheless, since it is an integrative marker of poor outcome,
directing some attention to the occurrence of VA failure
remains clinically relevant.
Lastly, given the moderate size of the AVG group, the non-
significant association between VA complications and outcomes
observed in this group may be due to a lack of statistical power.
Clinical implications and perspectives
This study points to the strong association between AVF throm-
bosis and patient survival in dialysis. Even in the absence of ad-
ditional evidence, clinicians should be cognizant that patients
with AVF thrombosis have immediate and midterm increased
mortality. VA failure could hence serve as an integrative short
and midterm risk stratifier in HD patients.
Given that rapid access restoration is seemingly associated
with a milder increase in subsequent mortality, clinicians
should be aware of the possible role of urgent revascularization.
This result could help in prioritizing VA restoration in vascular
surgery departments. In addition, as the increase in risk appears
to persist after VA thrombosis, these patients may consequently
require aggressive general therapeutic interventions in addition
to their urgent revascularization. Underlying conditions poten-
tially responsible for VA failure should also be investigated and
eventually corrected. An accurate coagulation assessment may
be required as well as close monitoring of nutritional and in-
flammatory status. Finally, targeting the risk factors of uraemic
vasculopathy may also be beneficial in preventing VA complica-
tions [22].
Careful medical follow-up and multidisciplinary manage-
ment after the occurrence of thrombosis could be crucial to re-
duce VA thrombosis rates and associated mortality in this
population of patients.
CONCLUSION
AVF/AVG thrombosis is strongly associated with increased
all-cause and CV mortality in patients on maintenance HD, es-
pecially in the first 90 days after the event and when access is
restored >7 days after thrombosis. Consequently, clinicians
should pay particular attention to the timing of VA restoration
as well as the management of these patients following VA res-
toration. In all instances, AVF thrombosis should be considered
as a major clinical event. The clinical relevance of targeting
overall patient risk with more aggressive treatment after VA
restoration warrants further exploration in dedicated trials.
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